Our study took in consideration the “HER2 low status”, which includes 1 + and 2 + non-amplified cases, associated with a discrepancy rate reaching almost 19.5% between the primary CRC and its paired metastasis. The gene discussed is ERBB2; the disease is colorectal carcinoma.